Findings

What do systematic reviews say?

16 questions · 16 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 25%GRADE not reported 0 · 0%Very low 6 · 37.5%Low 0 · 0%Moderate 1 · 6.3%High 5 · 31.3%

Ceftazidime vs 7 days injectable benzylpenicillin + injectable gentamicin

All‐cause mortality maximum · neonates with early‐onset sepsis

1 finding from 1 review

Antibiotic regimens for early‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 55 participants
Very low

Ceftazidime vs 7 days injectable benzylpenicillin + injectable gentamicin

Serious adverse events maximum · neonates with early‐onset sepsis

1 finding from 1 review

Antibiotic regimens for early‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 55 participants
Very low

Intravenous ceftazidime with tobramycin vs ciprofloxacin

Eradication of P aeruginosa from the respiratory tract: number of participants testing negative for P aeruginosa at 3 months and remaining free until 15 months · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intravenous ceftazidime with tobramycin vs ciprofloxacin

FEV1 % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 285 participants
High

Intravenous ceftazidime with tobramycin vs ciprofloxacin

FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 285 participants
High

Intravenous ceftazidime with tobramycin vs ciprofloxacin

Mean weight‐for‐age z‐score · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 285 participants
High

Intravenous ceftazidime with tobramycin vs ciprofloxacin

Frequency of infective pulmonary exacerbations: number of participants experiencing an exacerbation · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Intravenous ceftazidime with tobramycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with oral ciprofloxacin (high certainty).

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
RR 0.78 [0.55, 1.1]
1 study · 285 participants
High

Intravenous ceftazidime with tobramycin vs ciprofloxacin

Isolation of other micro‐organisms from the respiratory tract: number of participants isolating other micro‐organisms within the 15‐month · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Intravenous ceftazidime with tobramycin leads to higher isolation of other micro‐organisms from the respiratory tract:… compared with oral ciprofloxacin (high certainty).

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
RR 2.07
1 study · 285 participants
High

Intravenous ceftazidime with tobramycin vs ciprofloxacin

Adverse effects of antibiotics · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Intravenous ceftazidime with tobramycin probably leads to lower adverse effects of antibiotics: compared with oral ciprofloxacin (moderate certainty).

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
RR 0.97
1 study · 285 participants
Moderate

Intervention not reported

Ceftazidime (No direct RCT) · people with cirrhosis and spontaneous bacterial peritonitis

It is very uncertain whether the intervention changes ceftazidime (No direct RCT) (very low certainty).

1 finding from 1 review

Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network… 2019 · Cochrane Headline outcomes only
HR 1.15 [0.17, 6.37]
Studies not reported
Very low

Cefepime vs ceftazidime

All‐cause mortality maximum · neonates and children with hospital‐acquired pneumonia

It is very uncertain whether cefepime changes all‐cause mortality Maximum compared with ceftazidime (very low certainty).

1 finding from 1 review

Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes only
RR 0.14 [0.01, 2.55]
1 study · 30 participants
Very low

Cefepime vs ceftazidime

Serious adverse events maximum · neonates and children with hospital‐acquired pneumonia

It is very uncertain whether cefepime changes serious adverse events Maximum compared with ceftazidime (very low certainty).

1 finding from 1 review

Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes only
RR 0.14 [0.01, 2.55]
1 study · 30 participants
Very low

Cefepime vs ceftazidime

Treatment failure Maximum · neonates and children with hospital‐acquired pneumonia

It is very uncertain whether cefepime changes treatment failure Maximum compared with ceftazidime (very low certainty).

1 finding from 1 review

Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes only
RR 0.5 [0.15, 1.64]
1 study · 30 participants
Very low

Cefepime vs ceftazidime

Health‐related quality of life Maximum · neonates and children with hospital‐acquired pneumonia

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cefepime vs ceftazidime

Mortality (pneumonia-associated) · neonates and children with hospital‐acquired pneumonia

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cefepime vs ceftazidime

Non‐serious adverse events Maximum · neonates and children with hospital‐acquired pneumonia

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found